. We aimed at assessing the ESL impact on seizure frequency and quality of life in PPOS with a particular attention to sleepiness and depression. Methods: We evaluated 50 adult PPOS (>18 years; 48 AE 14 years-old; 23 males) treated with adjunctive ESL for !2months with a retrospective multi-centric design. Clinical files of the last 2 years were reviewed checking for monthly seizure frequency, treatment retention rate, adverse drug reactions (ADRs), concomitant anti-epileptic drugs and behavioural scales for sleepiness (Stanford Sleepiness Scale, SSS, and Epworth Sleepiness Scale, ESS), depression (Beck Depression Inventory-II, BDI) and overall quality of life (QOLIE-31). Results: At the end of 96 AE 28 days of ESL treatment, the mean seizure reduction was 56%; 60% of patients had seizure reduction above 50%, with a 31% of the whole population becoming seizure free. We reported 16 ADRs with 4 hyponatremia. Retention rate was 76%. Patient reported less sleepiness after ESL (SSS, p = 0.031; ESS, p = 0.0000002). Before ESL, 38% of patients had pathologic BDI scores, which normalized in most of them (73%) after ESL (BDI improvement, p = 0.000012). These scores resulted in an amelioration of quality of life (QOLIE-31, p = 0.000002). Conclusions: ESL is a safe and effective anti-epileptic drug in a real life scenario, with an excellent behavioural profile for the overall quality of life and, in particular, for sleepiness and depression.
Introduction
Epilepsy is among the most common neurologic disorders. About 5-10% of people will have an unprovoked seizure by the age of 80 [1] , and the chance of experiencing a second seizure is between 40-50% [2] .
Despite the existence of a wide range of commonly used antiepileptic drugs (AED), approximately 30% of patients with epilepsy requires combination of two or more AEDs in order to achieve seizure control [3] and some of them may encounter significant adverse effects which reportedly hamper their quality of life [4, 5] .
Eslicarbazepine acetate (ESL) is a third-generation member of the dibenzazepine family, after Carbamazepine (CBZ) and Oxcarbazepine (OXC), and its main mechanism is the sodium channel blockade. It was approved in 2009 by the European Medicines Agency and in 2013 by the US Food and Drug Administration with the indication of adjunctive therapy in adult people with refractory partial-onset seizures (PPOS), with or without secondary generalization (studies BIA-2093-301, BIA-2093-302 and BIA-2093-303) [6] . Considering that adverse effects and poor seizure control are the most influential factors in worsening life quality of patients undergoing therapy for epilepsy [4, 7, 8] , we aimed to understand how ESL, through its efficacy and tolerability, would impact on well-being in our population of PPOS. Furthermore, since dibenzazepines are known for their mood stabilizing effect and their positive effect on mood disorders [9] , we considered clinical scales specifically dedicated to depression [10] and quality of life thoroughly validated in epileptic populations. We preferred a retrospective study since it gave us the possibility to analyse the impact of ESL in a "real life scenario", without the constraints of interventional studies.
Methods
Present protocol was approved by local etic committees of Campus Biomedico University of Rome and Sapienza University of Rome.
We retrospectively evaluated 50 adult PPOS (>18 years; 48 AE 14 years-old; 23 males, 46%) treated with adjunctive ESL for !2months. The type of epilepsy was temporal lobe epilepsy for 47, frontal lobe epilepsy for 1 and occipital lobe epilepsy for 2 subjects; 30 PPOS had symptomatic and 20 PPOS had cryptogenic epilepsy. Six PPOS (12%) had partial simple seizures, 19 PPOS (38%) complex partial seizures, 11 PPOS(22%) secondarily generalized partial simple seizures and 14 PPOS (28%) secondarily generalized complex partial seizures. PPOS with >1 seizure/month in the last 3 months before ESL first assumption were enrolled in outpatients' clinics of the department of Neurology of Campus Bio-Medico University of Rome and the Department of Neurosciences of Sapienza University of Rome. Clinical files of the last 2 years were reviewed checking for monthly seizure frequency, type of seizures, treatment retention rate, Adverse Drug reactions (ADRs) and serious ADRs (SADRs), concomitant AEDs. According to seizure monthly rate changes, patients with a reduction !50% were defined as responders, while those with a reduction <50% as nonresponders. We also checked for measures of sleepiness by Stanford Sleepiness Scale (SSS; measuring instantaneous sleepiness), Epworth Sleepiness Scale (ESS, chronic sleepiness [11] ), depression by Beck Depression Inventory-II (BDI) scale [12] and quality of life (QOLIE-31). QOLIE31 is a strongly validated test in the assessment of quality of life in people affected by epilepsy, so widely used that is translated in more than 25 languages [7] . Patients files with two clinical evaluations obtained before starting ESL and after at least 2 months of ESL assumption were used for subsequent analysis. Monthly seizure frequency obtained after 2 months of ESL treatment was considered for analysis. The availability of behavioural scales was not an inclusion criteria for the present study. Under add-on therapy with ESL, seizure frequency reduced of !50% in 60% of patients, with 31% of the total number of patients achieving seizure freedom (Fig. 1) . The analysis of the type of seizure did not reveal any significant difference in the size of seizure type groups after adjunction of ESL treatment. Sixteen patients (32%) experienced ADRs (the most common were vertigo in 6 (12%) and hyponatremia in 4 (8%), (see the Table 1 for frequencies) and of these 12 (24%) withdrew treatment due to this ADRs; 2 (4%) of them presented SADRs (symptomatic hyponatremia). Thus, retention rate was 76%. ESL add-on therapy favoured a reduction of the number of concomitant drugs (0,58 AE 0,71 mean drug reduction after ESL introduction; range À3, 1, chi 2 = 50, 52, sig. = ,0001, Cohen's d 1,24). Co-medications before and after ESL add-on were reported in Table 2 . Behavioural scales were available in 33 patients (23 patients with all the scales: BDI-II, ESS, SSS and Qolie-31; for the availability of each scale please refer to Table 5 (13,7 AE 9,2 at baseline, range 0-41; 6,1 AE 7,1 after ESL, range 0-27; p = 0,000012, Cohen's d 0,79; Fig. 2,) . Before ESL, 38% of patients had pathologic BDI scores (BDI ! 14) and 73% of them achieved a normalization of BDI scores after ESL (Fig. 3) . Only 13% of patients had excessive daytime sleepiness (ESS ! 9) before ESL and it was reduced at 3,6% after ESL add-on treatment. These positive effects on seizure control and behaviour resulted in an overall amelioration of quality of life (QOLIE-31 score 49,4 AE 17,8 at baseline, range 11-85; 62,6 AE 16,0 after ESL, range 30-91; p = 0.000002, Cohen's d À0,91; Fig. 2 ). We also analysed separately each of the seven domains of QOLIE31 to evaluate the impact of ESL adjunctive therapy on each domain. We found a trend towards improvement with therapy in every single domain (see Table 3 for statistics). The domains that seemed to improve the most after add-on therapy with ESL were: emotional well-being, overall quality of life and cognition. The positive impact of ESL add-on therapy was evident in every behavioural scale we tested. It has been reported that the reduction of seizure frequency is paralleled by an amelioration of quality of life, mood and other behavioural aspects [13] , thus we evaluated these correlation is our patient, but we found no correlation. There was no correlation between percent changes of seizure frequency and changes of behavioural scales during the observed period. Thus, we tried to further understand this result by dividing patients into two groups, non-responder' group (seizure reduction <50%) and responders group (seizure reduction !50%) and verifying differences of behavioural scales between these groups. Groups were not different by age, gender, number of AED at T0 and at T1 and years of disease. Non-responders had higher number of age of disease and number of past AEDs (Table 5) and experienced more ADR then responders (10 vs 6 respectively; chi 2 0,222, sig = 0,002) As it is shown in Fig. 2 , both groups had an improvement in ESS, BDI-II, QOLIE31 with similar distribution, being slightly better for responders' group:
Statistical analysis
Responders' Group: BDI T1-T0: p = ,007; ESS T1-T0 p = ,0001; QOLIE T1-T0 p = ,002; SSS T1-T0 = ,191. Non-responders' Group: BDI T1-BDI-T0: p = ,005; ESS T1-T0 p = ,015; QOLIE T1-T0 p = ,022.
ANOVA analysis using Group (responders vs non-responders) as factor did not show any significant difference for behavioural scale changes (BDI T1-T0, ESS T1-T0, SSS T1-T0, QOLIE T1-T0).
These data suggest that amelioration of quality of life, sleepiness and mood induced by ESL introduction is facilitated also by other factors which are independent by the mere seizure reduction.
We further tested for a correlation among behavioural scale (ESS, SSS, Qolie-31 and BDI) changes and we found a straight relationship between depression, sleepiness and quality if life in our patients (Table 4) .
Discussion
Our real-life experience with ESL showed that ESL add-on treatment offers great antiepileptic efficacy together with a favourable profile paralleling with an amelioration of sleepiness, depression and quality of life.
Most of our patients (60%) showed a clinically significant reduction of seizure frequency and one third of the whole sample became seizure free. This result is particularly relevant considering that enrolled patients were drug-resistant with a long epilepsy history and complex poly-therapies. Actually, our retrospective analysis included those patients receiving ESL immediately after its commercialization in Italy and thus several patients with a severe drug-resistant epilepsy waiting for the newest drug to test. The mean seizure reduction after ESL adjunctive treatment in our sample (56%) resembles that of phase III trial [6, 7] , while the efficacy on responder rate was pretty higher in our sample [14] thus confirming the ESL add-on treatment efficacy also in a real life scenario, where dosage titration, complexity of drug treatment and physiological patient-specific issues are more realistic that those of clinical trials. Non-responders' PPOS had a longer disease and a higher number of past AED and thus an expected higher a priori probability to be drug-resistant [15] . The ESL efficacy paralleled with good tolerance and compliance, however, one fourth of our patients discontinued ESL, mainly because of ADRs. Adverse effects (AE) reported in clinical trials were dose-dependent [16] and mainly involving central nervous (diplopia, dizziness, headache, vertigo and somnolence) and gastrointestinal system. Validation trials reported few serious ESL-related AEs and these events were generally mild to moderate, predictable, manageable and occurring during the early stages of treatment [17] [18] [19] . Compared to other dibenzazepines the major adverse effect appears to be hyponatremia (defined as any report of Na 135 mmol/l); during phase III studies hyponatremia was found in 18% of the patients receiving ESL, in particular on those patients with significant comorbidities and poly-therapy, versus 6% in patients receiving placebo [20] . In our sample, we recorded a higher amount of ADR leading to discontinuation of the ESL (24%), in particular dizziness, but a minor percentage of significant hyponatremia. Of 16 patients with ADRs, 4 reported hyponatremia and two of them had symptomatic hyponatremia, accounting for 8% and 4% of our population, respectively. It is possible that the different comorbidities of our patients and the knowledge of these predictable AE lead us to perform a careful monitoring of blood sample and behavioural suggestions to our patient to prevent hyponatremia incidence.
Despite the high percentage of ADR, we found an amelioration in all the behavioural parameters we assessed for sleepiness, depression and quality of life. Actually, in a subgroup of our patients, ESL add-on treatment ameliorated both acute and chronic sleepiness as testified by two different tests (SSS and ESS, respectively). Pathological scores of sleepiness normalized after ESL treatment in most of patients receiving specific questionnaires. It was an unexpected result considering the largely known negative impact on cognitive functioning of ESL drug class, the dibenzazepines [21] . It can be explained by the peculiar pharmacokinetic and pharmacy-dynamic features of ESL. Actually, after oral administration, ESL is promptly and extensively metabolized in the liver to an active metabolite that has a linear pharmacokinetic profile, a low binding ratio to plasma proteins Fig. 3 . BDI-II before (t0) and after (t1) Eslicarbazepine treatment in responders (group 1) and non responders (group 1). legend: t-test analysis demonstrated a significant difference (p < 0.05, see the text) of BDI (Beck Depression Inventory scale) values at T1 (after Eslicarbazepine treatment) respect to those at T0 (before Eslicarbazepine treatment). Before ESL 38% of patients had pathologic BDI scores and of these patients 73% achieved a normalization of BDI scores after ESL (pathological cut-off is over 14, dotted line).
values out of the interquartile range (25 -75 percentile). (<40%), and a half-life of 20-24 h, thus allowing a once-daily administration [22] with a night assumption that minimize the incidence of dizziness related to the plasma peak concentration. Depletion is mainly renal, unchanged or as glucuronide conjugates.
One of the main difference between ESL and other dibenzazepines is the low level of epoxides produced after liver metabolism, which are allegedly related to central nervous system adverse effects [7] [8] [9] [10] . This last feature is likely to cause the favourable profile of ESL on sleepiness of our patients. At our baseline assessment, more than one third of patients tested for depression presented with pathological scores, in line with the incidence of depressive symptoms in drug-resistant epileptic patients [4, 17] . After ESL addon treatment, depression scales re-assessment demonstrated normal values in most of them. The combination of these two positive results on sleepiness and depression were understandably reflected in an amelioration of the global quality of life as assessed by an epilepsy-specific questionnaire. These improvements appeared to be independent from age and sex and they seemed to be only partially related to seizure reduction. Actually, when we tried to correlate the behavioural scores to seizures rate response we did not find any significant result. Thus, we tried to understand this phenomenon by a sub-analysis assessing the behavioural scores changes in both of the group of responders and nonresponders. It revealed that the amelioration of sleepiness, depression and quality of life was significant in both of them, even if it was stronger in responders' one. Thus we can speculate that the ability of ameliorating these behavioural scores might depend on factors other than merely its seizure control activity; possibly one of these factors could be the known positive effect of dibenzazepines family drugs on major depression. We suppose that the behavioural effect of therapy with ESL could depend strongly on its seizure control ability and good tolerability, but also, and not inconsistently, on its intrinsic anti-depressant and mood stabilizer effect [22, 23] . The major limitations of the present study are the lack of a randomised placebo control that might reduce the significativity of the ESL effects. Furthermore, the retrospective real-life design of the study allowed changes in comedications, so that the behavioural effects could be also explained by the reduction of other AEDs. The short follow-up does not allow to test the longterm effects of ESL add-on therapy.
In conclusion we demonstrated in a real-life scenario that ESL, used as add-on treatment, is a well tolerated anti-epileptic drug with an excellent behavioural profile resulting in a significant amelioration not only of the overall quality of life, but also of specific behavioural aspects as depression and sleepiness, and these latter effects seems to be only partially dependent on seizure reduction. This clinical profile positively expands the range of drugs at clinician's and patient's disposal, in particular in those patients experiencing behavioural side effects such as sleepiness and depression.
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